Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

The efficacy and safety of using low-dose cyclophosphamide, fludarabine and thymoglobulin in allogeneic hematopoietic stem cell transplantation for transfusion-dependent non-severe aplastic anemia：a retrospective study.

View Full Paper
Ask AI
Bookmark
Share

Authors

TWTao WangJWJia WeiLMLiangming Ma

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows that low-dose cyclophosphamide is safe and effective for hematopoietic stem cell transplantation in transfusion-dependent non-severe aplastic anemia, with favorable engraf

Key Points

  • This study aims to analyze the efficacy and safety of hematopoietic stem cell transplantation for transfusion-dependent non-severe aplastic anemia using a specific conditioning protocol.
  • Retrospective analysis of 31 patients with transfusion-dependent non-severe aplastic anemia.
  • Conditioning protocol included low-dose cyclophosphamide, fludarabine, and thymoglobulin.
  • Evaluated engraftment time, incidence of graft-versus-host disease, and related complications.
  • All 31 patients successfully engrafted with a median neutrophil engraftment time of 19 days for HLA matched donors and 23 days for haploidentical donors.
  • The study reported a 93% event-free survival and 95% overall survival at 2 years post-transplant.
  • No patients developed grade III or IV adverse cardiac and liver toxicity.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db5ahttps://doi.org/10.1182/blood-2025-5986
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A novel reduced-toxicity conditioning regimen with busulfan/fludarabine/cyclophosphamide/anti-thymocyte globulin for severe aplastic anemia2025
  2. 2A novel thiotepa-containing conditioning regimen for haploidentical hematopoietic cell transplantation in pediatric aplastic anemia at high risk of cardiotoxicity2025
  3. 3A prospective, open, single-arm clinical trial of fludarabine- cyclophosphamide-porcine anti-lymphocyte globulin conditioning combined with matched sibling donor hematopoietic stem cell transplantation in the treatment of severe aplastic anemia2026
  4. 4Post-Transplant Cyclophosphamide Allows Allogeneic Hematopoietic Stem-Cell Transplantation Across Donor Types for Nonmalignant Hematologic Diseases2026
  5. 5Fludarabine, cyclophosphamide, and melphalan (FCM) preconditioning in haploidentical hematopoietic stem cell transplantation for severe aplastic anemia: Update of a prospective, multicenter, single-arm clinical study2025